ngenla
Generic: somatrogon-ghla·Code: hGH-CTP
ngenla: sourced relationships with 2 companies · 1 FDA decision.
ngenla evidence translation
What we can confirm
1 FDA record
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about ngenla, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
growth disturbance due to insufficient secretion of growth hormone
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| OPKO HEALTH, INC. (OPK) growth disturbance due to insufficient secretion of growth h… | Approved |
| PFIZER INC (PFE) Reported 2023-06-27 · Current development: unknownSource | Approved |
| PFIZER INC (PFE) Reported 2023-06-27 · Current development: unknownSource | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with ngenla?
ngenla has dated SEC/FDA relationship records for OPKO HEALTH, INC., PFIZER INC.
What is ngenla's latest FDA decision?
The most recent tracked FDA decision for ngenla is Approval, dated June 27, 2023.